U.S. Markets closed

NeoStem completes patient enrollment in Phase 2 AMR-001 trial

NeoStem announced completion of enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blind placebo-controlled Phase 2 clinical trial testing NeoStem's lead product candidate, AMR-001, an autologous adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction. With infusion of the target population of 160 patients complete, NeoStem expects data readout in 3Q14.